Released Nov 5, 2026, after the close
10-Q filed Nov 5, 2026, 36 days after period end · 0001628280-26-071075
CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2026.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $13.83M | $14.69M | $13.37M | $10.51M |
| Net Income | -$14.16M | -$12.87M |
CVRx, Inc. · CIK 1235912 · Engraved from SEC EDGAR
| -$13.10M |
| -$9.01M |
| EPS Diluted | -$0.52 | -$0.49 | -$0.57 | -$0.43 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Total revenue for the third quarter of 2026 was $13.8 million, a decrease of $0.9 million, or 6%, from the three months ended September 30, 2025.¶2
Net loss was $14.2 million, or $0.52 per share, for the three months ended September 30, 2026, compared to a net loss of $12.9 million, or $0.49 per share, a year earlier.¶3
For the full year of 2026, the Company now expects total revenue between $56.0 million and $57.0 million, and expects fourth quarter 2026 total revenue between $11.7 million and $12.7 million.¶4¶5
Active implanting centers in the U.S. increased to 262 as of September 30, 2026, compared to 250 as of September 30, 2025.¶6¶7
John Landry was appointed Chief Financial Officer effective November 6, 2026, succeeding Jared Oasheim.¶8¶9